Implications of very low risk prostate cancer assessed

September 20, 2013
Implications of very low risk prostate cancer assessed

(HealthDay)—The risk of adverse findings at surgery for men with very low risk (VLR) prostate cancer is significantly lower than for those with low risk (LR), according to research published in the October issue of the The Journal of Urology.

Jeffrey J. Tosoian, M.D., of Johns Hopkins Hospital in Baltimore, and colleagues prospectively studied the oncologic outcomes at surgery in 7,486 men with LR (7,333 patients) and VLR (153 patients) prostate cancer who were candidates for active surveillance.

Upon final pathology, the researchers found that 21.8 percent of men with LR prostate cancer had a Gleason score upgrade and 23.1 percent had non-organ confined cancer. However, for men with VLR prostate cancer, only 13.1 percent required a Gleason score upgrade and 8.5 percent exhibited non-organ confined cancer on final pathology. Overall, men with LR prostate cancer were 1.89- and 2.06-fold more likely to experience a Gleason score upgrade or non-organ-confined cancer, respectively, compared with men with VLR prostate cancer.

"The likelihood of a more aggressive pathological phenotype differs among men with LR and VLR who are eligible for active surveillance," the authors write. "This may provide additional guidance in identifying subjects most appropriate for surveillance and counseling those men considering surveillance as an alternative to immediate curative intervention."

Explore further: Racial discrepancy in oncologic outcomes for low-risk PCa

More information: Abstract
Full Text

Related Stories

Racial discrepancy in oncologic outcomes for low-risk PCa

June 18, 2013
(HealthDay)—Among men with very-low-risk prostate cancer (PCa) who meet criteria for active surveillance but undergo radical prostatectomy, African-American race is associated with poorer outcomes, with higher rates of ...

Updated 'Partin Tables' tool now available to predict prostate cancer spread

January 4, 2013
Prostate cancer experts at Johns Hopkins have developed an updated version of the Partin Tables, a tool to help men diagnosed with prostate cancer and their doctors to better assess their chance of a surgical cure. The updated ...

Mayo Clinic genomic analysis lends insight to prostate cancer

May 23, 2013
Mayo Clinic researchers have used next generation genomic analysis to determine that some of the more aggressive prostate cancer tumors have similar genetic origins, which may help in predicting cancer progression. The findings ...

Prostate cancer tumors' aggressiveness may be inherently fixed

August 15, 2013
A new study of prostate cancer suggests that a tumor's aggressiveness is inherently fixed at the time of its appearance, although diet, lifestyle and environmental factors may trigger progression of the disease in low-level ...

Genetic test could identify which prostate cancers require treatment

September 11, 2013
The level of expression of three genes associated with aging can be used to predict whether seemingly low-risk prostate cancer will remain slow-growing, according to researchers at the Herbert Irving Comprehensive Cancer ...

Prostate cancer screening: New data support watchful waiting

August 14, 2013
Prostate cancer aggressiveness may be established when the tumor is formed and not alter with time, according to a study published in Cancer Research, a journal of the American Association for Cancer Research.

Recommended for you

New approach attacks 'undruggable' cancers from the outside in

January 23, 2018
Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer. However, many of the most common cancer-causing genes are so central to ...

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.